Cytek Biosciences, Inc. completed the acquisition of Flow Cytometry & Imaging business unit of Luminex Corporation for $44.9 million.
February 27, 2023
Share
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for approximately $46.5 million on February 13, 2023. The purchase price, payable in cash is subject to certain customary adjustments at closing. Under the asset purchase agreement, Cytek Biosciences agreed to acquire certain assets relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services of Luminex. The sale is expected to close within 30 days, subject to customary closing conditions.
Cytek Biosciences, Inc. (NasdaqGS:CTKB) completed the acquisition of Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $44.9 million on February 28, 2023. Cytek Biosciences also assumed certain liabilities of the Flow Cytometry & Imaging (FCI) business.
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
CYTEK BIOSCIENCES, INC. 
